Sympathetic Ophthalmia

Slides:



Advertisements
Similar presentations
F. Kianersi M.D 1387 / 12 / 1.  Patients with uveitis have cataracts: More often, and at an Earlier Age than the general population.  Main etiological.
Advertisements

Clinicopathologic Case
1 1© 2008 Universitair Ziekenhuis Gent 1 Vogt-Koyanagi-Harada Syndrome Prof. dr. Ph. Kestelyn.
Learning Outcomes By the end of this lecture the students would be able to  Diagnose OGI of the eye  Describe the complications of OGI  Describe the.
GH.Naderian, M.D.. Supra choroidal hemorrhage Cystoid macular edema Retinal detachment.
DR ALI SALEHI TOXIC ANTERIOR SEGMENT SYNDROM (TASS)
Uveal Tract Diseases.
CENTRAL SEROUS RETINOPATHY (C.S.R)(C.S.C)
Intraocular lens (IOL) Dislocation M.R. Akhlaghi MD.
Wednesday AM report Uveitis and Cogan’s syndrome.
Retinal Anatomy Dr. Miratashi.
Diabetic Retinopathy Steven Sanislo, M.D. Assistant Professor Stanford University Department of Ophthalmology.
ORBITAL FRACTURES Brig Amer Yaqub FCPS, FRCSEd ANATOMY OF ORBIT.
SYMPATHETIC OPHTHALMIA
Diagnosis Chronic glaucoma with secondary angle closure following central retinal vein occlusion with hemorrhagic infarction of retina and neovascularization.
Acute and Chronic visual loss By Dr. ABDULMAJID ALSHEHAH Ophthalmology consultant Anterior Segment and Uveitis consultant.
EVALUATION OF ANTERIOR CHAMBER SULCUS SUPPORTED INTRAOCULAR LENS BY PROF. HAMED NASER EL- DIN TAHA HAED OF OPHTHALMOLOGY DEPT. SAUDI GERMAN HOSPITAL JEDDAH.
AlphaCor TM : A Novel Approach to Minimize Late Post-operative Complications V. Ngakeng MD, M. Price PhD. MBA, F. Price MD.
Dr. Abdullah Al-Amri Ophthalmology Consultant
Siderosis Bulbi Zamzam Al-baker,MD Consultant Opthalmology
Assist. Lecturer of Ophthalmology
Chronic Visual Loss. CHRONIC VISUAL LOSS 1. Measure intraocular pressure with a tonometer 2. Evaluate the nerve head 3. Evaluate the clarity of the lens.
Diffuse infiltrating retinoblastoma > >. Ocular and General History  5 years old boy  Unremarkable birth history (BBW: 2800g, full-term)  No preceding.
Tubulointerstitial Nephritis and Uveitis (TINU) Syndrome Sana Khochtali Imen Ksiaa Anis Mahmoud Bechir Jelliti Department of Ophthalmology Fattouma Bourguiba.
Central serous chorioretinopathy and uveitis Central serous chorioretinopathy and uveitis Rim Kahloun, MD Sonia Zaouali, MD Moncef Khairallah, MD Moncef.
Centre of Ophthalmology University of Tuebingen, Germany
Chapter 11. Glaucoma Concept: Those suffer from pathologic high IOP which is sufficient to cause excavation of optic disc, optic atropy and characteristic.
Pathology of thyroid 2 Dr: Salah Ahmed. Thyroiditis - inflammation of the thyroid gland, includes a group of disorders characterized by some form of thyroid.
Uveitis CTP Egla Rabinovich, Sheila Angeles-Han, Drew Lasky and Mindy Lo For the CARRA Uveitis working Group.
OCULAR MANIFESTATIONS OF SARCOIDOSIS
Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Inhibition of Neovascularization but Not Fibrosis.
HLA-B27 Associated Anterior Uveitis
In the name of God.
Dr.Ravi kant Associate Professor Medicine ,AIIMS Rishikesh
SYMPATHETIC OPHTHALMIA: EXPERIENCE IN A TERTIARY REFERRAL CENTER
Classification of uvietis: 1.Anatomical. 2.Clinical. 3.Etiological.
Anterior Uveitis (iritis)
Presumed tuberculosis-associated uveitis: rising incidence and widening diagnostic criteria in non-endemic area Nikolas Krassas1, Jane Wells1, Christine.
Macular Epiretinal membrane
Sympathetic Ophthalmitis
E POSTER A case of Best Vitelliform macular dystrophy
IDIOPATHIC SPECIFIC UVEITIS SYNDROMES
EPISCLERITIS AND SCLERITIS
AGE-RELATED MACULAR DEGENERATION (AMD)
Neuro-ophthalmology.
VR Disorders Retinal Detachment (RD)
Uveitis.
OTHER ACQUIRED MACULOPATHIES
Adamantiades –Behjet Disease (ABD) 1-Is a chronic , relapsing occlusive vascular is of unknown etiology, 2-Characterized , in part by a uveitis that.
Phacoemulsification in patients with Diabetes Mellitus
Fuch,s Heterachromic Uvitis
SARCOIDOSIS Idiopathic multisystem disorder
IN THE NAME OF GOD.
In The Name of God.
COMPLICATIONS OF UVEITIS
BEHÇET’S DISEASE Idiopathic multisystem disease More common in men
THERAPY FOR UVEITIS. THERAPY FOR UVEITIS OBSERVATION For development of complications For change in the appearance / severity/progression.
Visual prognosis among traumatic hyphemas
Atypical case of Vogt- Koyanagi-Harada disease
Inflammatory Chorioretinopathies of Unknown Etiology
Multiple evanescent white dot syndrome
Intraocular lens (IOL) Dislocation
SICKLE CELL DISEASE OPHTHALMIC MANIFESTATIONS
A I II 1 2 H1 H0 20/ logMAR B F+F C D Figure 1. (A) Pedigree of a family with a unilaterally affected father discovered to be mosaic (H1) for a high.
Uveitis Haneen Omar Abu Hani.
Gowri Pachigolla, M.D., Steven Verity, M.D.,
The Sclera.
Iris Biopsy in Uveitis: Masquerade Syndrome
Presentation transcript:

Sympathetic Ophthalmia بسم الله الرحمن الرحيم Sympathetic Ophthalmia F. Kianersi M.D 1390 / 7 / 21

Sympathetic Ophthalmia RED EYE and TRAUMA Sympathetic Ophthalmia SO is a Rare, Bilateral, Diffuse Granulomatous, Autoimmune Panuveitis that may develop after either surgical or accidental trauma to 1 eye (the Exciting eye), followed by a latent period and the appearance of Uveitis in the uninjured fellow eye (the Sympathizing eye). Sympathetic ophthalmia is always a consideration in major ocular trauma. Note that you have only about 5-7 days to decide whether or not to remove the eye for once the uveitis has begun, enucleation is no longer beneficial. 2

History The first written reference to appeared about 1000 A.D. Stating that "the right eye, when diseased, often gives suffering to the left. “ In the 16th century, Bartisch wrote in his textbook of ophthalmology that after injury in one eye, "the other good eye is in great danger.”

History Louis Braille was born on 1809. At the age of 3, Braille injured his left eye with a stitching awl from his father's workshop. This destroyed his left eye, and sympathetic ophthalmia led to loss of vision in his right eye. Braille was completely blind by the age of 4.

History The term Sympathetic Ophthalmia was coined by William MacKenzie in 1840. In 1905, Ernest Fuchs described the classical microscopic findings in SO. Since then the disease has became well recognized in ophthalmology.

Incidence A century ago, the reported incidence of SO was about 2% following injury to one eye. Significant improvements in the management of ocular trauma, together with the more widespread use of immuno - modulatory therapy, has led to an overall decrease in the SO.

Incidence The most recent minimum incidence is 3 out of every 10,000,000 cases of penetrating injury or surgery resulted in SO. It is thus obvious that the incidence of SO is extremely low.

Time of Onset after Trauma The time between the injury in the “exciting” eye and the onset of SO ranges from 5 days to 66 years. In recent reports, 1/3 of patients developed SO within 3 months and less than 1/2 did so within 1 year of injury.

Clinical Features SO is manifested by a gradual onset with a progressive course marked by frequent periods of worsening. Patients with SO typically present with asymmetric bilateral Panuveitis, with more severe inflammation in the exciting eye than in the sympathizing eye, at least initially.

Clinical Features Signs and symptoms in the sympathizing eye vary in their severity and onset, ranging from minimal problems in near vision, mild photophobia, and slight redness to severe granulomatous anterior uveitis.

Clinical Features Both eyes may show cellular infiltration in AC with mutton-fat KPs, thickening of the iris from lymphocytic infiltration, and PS formation.

Clinical Features The most common ocular findings in the anterior chamber are mutton fat KPs and variable degrees of inflammatory reaction.

Clinical Features The posterior segment involvement is the most characteristic and may include: Vitreous Cells, Retinal Vasculitis, Papillitis, Choroiditis, and Serous RD.

Clinical Features The most classic findings, are whitish-yellowish infiltrates which are usually seen in the peripheral choroid and are named Dalen-Fuchs nodules. They are seen in about one third of patients with SO.

Fluoresceine Angiography The F/A reveals multiple hyper-fluorescent sites of leakage at the level of the RPE during the venous phase, which persists into the late stage. There is often late staining of the optic nerve.

Histopathologic Features Diffuse, Granulomatous, Non - necrotizing infiltration of the Choroid with a predominance of Lymphocytes. Absence of inflammatory involvement of the Choriocapillaris and Retina.

Histopathologic Features Dalen-Fuch's nodule is made up of epitheloid cells and lymphocytes and is found between the RPE and the Bruch's membrane.

Etiology The precise etiology of SO is unknown. In the overwhelming majority of patients, there is a history of penetrating ocular injury complicated by incarceration of uveal tissue. SO may result from altered T-Iymphocyte responses to ocular self-antigens such as retinal S-antigen or to other retinal or choroidal melanocyte antigens.

Etiology There maybe a genetic predisposition to the development of the disease, as patients with SO are more likely to express HLA-DR4, DRw53, and -DQw3 haplotypes.

Surgical Procedures that may lead to SO Deep Vitrectomy Iridencleisis Trabeculectomy YAG laser Cyclodestruction Cyclocryotherapy Proton beam and helium ion irradiation for Choroidal Melanoma Secondary IOL placement Cataract extraction, particularly when the iris is entrapped within the wound Scleral Buckling

Differential Diagnostic Any causes of panuveitis, including: VKH, TB, Sarcoidosis, Syphilis, Fungi, Traumatic or Postoperative Endophthalmitis.

Differential Diagnostic The clinical presentations of SO and VKH may be strikingly similar; however, a history of prior ocular injury is typically absent in patients with VKH.

Clinical Course The course of SO is chronic, with frequent exacerbations, and if left untreated, leads to loss of vision and Phthisis Bulbi.

Complications Structural complications of SO include: Cataract,

Complications Structural complications of SO include: Cataract, Secondary Glaucoma,

Complications Structural complications of SO include: Cataract, Secondary Glaucoma, CME,

Complications Structural complications of SO include: Cataract, Secondary Glaucoma, CME, CNV,

Complications Structural complications of SO include: Cataract, Secondary Glaucoma, CME, CNV, Retinal Detachment,

Complications Structural complications of SO include: Cataract, Secondary Glaucoma, CME, CNV, Retinal Detachment, Retinal and Optic Nerve Atrophy,

Fluoresceine Angiography in Late Cicatricial Phase The areas correspond to Dalen-Fuchs nodules become atrophic, and appear on the angiogram as window defects.

Complications Structural complications of SO include: Cataract, Secondary Glaucoma, CME, CNV, Retinal Detachment, Retinal and Optic Nerve Atrophy, Subretinal Fibrosis and Choroidal Atrophy,

Complications Structural complications of SO include: Cataract, Secondary Glaucoma, CME, CNV, Retinal Detachment, Retinal and Optic Nerve Atrophy, Subretinal Fibrosis and Choroidal Atrophy, Phthisis Bulbi.

Management The course of SO is chronic, with frequent Exacerbations, and if left untreated, leads to loss of vision and Phthisis Bulbi. Every attempt should be made to salvage eyes with a reasonable prognosis for useful vision with meticulous and prompt closure of penetrating injuries.

Management Enucleation within 2 weeks of injury to prevent the development of SO should be considered in grossly disorganized globes with no discernible visual function. Although controversial, Enucleation may still be preferred to Evisceration as the operation of choice for the removal of ocular contents in severely injured eyes.

Management Enucleation of the exciting eye once SO has become established has not been shown to be beneficial in altering the disease course of the sympathizing eye.

Treatment The mainstay of therapy for SO is immunomodulatory therapy, initially with systemic Corticosteroids. Azathioprine, Methotrexate, Mycophenolate mofetil, Cyclosporine, Chlorambucil, Cyclophosphamide.

Treatment Topical corticosteroids, together with cycloplegic/mydriatic agents, are essential in the treatment of acute anterior uveitis associated with SO. Periocular Corticosteroids are used in the management of inflammatory recurrences and CME.

Prognosis SO remains a serious disease that may result in a very poor visual outcome without therapeutic intervention. With prompt and aggressive aggressive systemic immunomodulation, the visual prognosis of SO is good, with 50% of patients achieving a final visual acuity of 20/40 or better in at least 1eye.

SYMPATHETIC OPHTHALMIA RED EYE and TRAUMA SYMPATHETIC OPHTHALMIA (Bilateral Granulomatous Panuveitis after Trauma) Onset: 5 days to 66 years after penetrating trauma Onset: 33% at 3 mo., <50% after 1 year Cause: antigen-antibody interaction Risk: Very low Removal of injured eye after onset does not help Treatment: Aggressive Immunosuppressive therapy Sympathetic ophthalmia is always a consideration in major ocular trauma. Note that you have only about 5-7 days to decide whether or not to remove the eye for once the uveitis has begun, enucleation is no longer beneficial. 47

THANK YOU